Phase II trial using romidepsin after gemcitabine, dexamethasone, and cisplatin therapy in elderly transplant-ineligible patients with relapsed/refractory peripheral T-cell lymphoma: Study protocol

Satoshi Yamasaki, Akiko Kada, Hirokazu Nagai, Isao Yoshida, Ilseung Choi, Akiko M. Saito, Hiromi Iwasaki

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)

抄録

Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.

本文言語英語
ページ(範囲)469-474
ページ数6
ジャーナルActa medica Okayama
73
5
出版ステータス出版済み - 2019
外部発表はい

All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「Phase II trial using romidepsin after gemcitabine, dexamethasone, and cisplatin therapy in elderly transplant-ineligible patients with relapsed/refractory peripheral T-cell lymphoma: Study protocol」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル